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OBJECTIVES The study was done to determine whether the G20210A mutation in the prothrombin gene
increases the risk of recurrent venous thromboembolism (VTE), both alone and in
combination with factor V Leiden.
BACKGROUND Several inherited defects of coagulation are associated with increased risk of first VTE,
including a recently identified G20210A mutation in the prothrombin gene. However,
whether the presence of this mutation confers an increased risk of recurrent venous
thromboembolism is controversial.
METHODS A total of 218 men with incident venous thromboembolism were genotyped for the
prothrombin mutation and for factor V Leiden and were followed prospectively for recurrent
VTE over a follow-up period of 7.3 years.
RESULTS A total of 29 men (13.3%) suffered recurrent VTE. Five of the 14 carriers of the prothrombin
mutation developed recurrent VTE (35.7%; incidence rate 5 8.70 per 100 person-years),
while 24 of 204 individuals who did not carry the prothrombin mutation developed recurrent
VTE (11.8%; incidence rate 5 1.76 per 100 person-years). Thus, presence of the G20210A
mutation was associated with an approximate fivefold increased risk for recurrent VTE (crude
relative risk [RR] 4.93; 95% confidence interval [CI] 1.9–12.9; p 5 0.001; age-, smoking-,
and body mass index-adjusted RR 5.28; 95% CI 2.0–14.0; p 5 0.001). In these data,
recurrence rates were similar among those with an isolated mutation in the prothrombin gene
(18.2%) as compared to those with an isolated factor V Leiden mutation (19.2%). However,
all three study participants who carried both mutations (100%) suffered a recurrent event
during follow-up.
CONCLUSIONS In a prospective evaluation of 218 men, the presence of prothrombin mutation was associated
with a significantly increased risk of recurrent VTE, particularly among those who
co-inherited factor V Leiden. (J Am Coll Cardiol 2001;37:215–8) © 2001 by the American
College of Cardiology
Individuals with inherited defects of coagulation are at
increased risk for deep venous thrombosis and pulmonary
embolism. In particular, carriers of either a G20210A
mutation in the prothrombin gene (1–4) or the factor V
Leiden mutation (5–8) have an increased lifelong risk of
first venous thrombosis compared to unaffected individuals.
However, whether genetic carriers of these defects are at
significantly increased risk for recurrent venous thrombo-
embolism (VTE), and thus might benefit from lifelong
anticoagulation, is controversial. For example, while some
prospective studies report a significantly increased risk of
recurrent VTE among carriers of factor V Leiden (9,10),
other studies suggest these risks may be small and limited to
individuals with multiple inherited and/or acquired defects
of hemostasis (11,12).
With respect to the prothrombin mutation, data concern-
ing the risk of recurrent VTE are scant and inconsistent. For
example, although two prospective studies have shown no
increase in the risk of recurrent VTE in association with the
prothrombin mutation (12,13), De Stefano and colleagues
have recently demonstrated in a retrospective study that the
rate of recurrent VTE among carriers of the prothrombin
mutation was increased only among those who also were
carriers of factor V Leiden (14). Thus, whether an isolated
mutation in the prothrombin gene increases the risk of
recurrent venous thromboembolism remains unclear. To
provide further data on this issue, we evaluated the role of
the G20210A mutation as a potential risk factor for recur-
rent venous thromboembolism among a cohort of 218 men
followed over an average period of 7.3 years.
METHODS
Study subjects included 218 participants in the Physicians’
Health Study (PHS) who had a documented VTE and were
then followed for recurrent thromboembolic events. As
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described elsewhere (15), the PHS is a prospective cohort of
22,071 U.S. male physicians 40 to 84 years old at study
entry who were randomized in a double-blind, placebo-
controlled, 2 3 2 factorial design to low-dose aspirin,
beta-carotene, both, or neither and then were followed for
the occurrence of vascular diseases and cancer.
During follow-up, questionnaires regarding incident car-
diovascular events and the presence of established risk
factors were completed annually by each participant. Re-
ported episodes of deep vein thrombosis (DVT) or pulmo-
nary embolism (PE) were confirmed by review of hospital
records, death certificates, and autopsy reports. Diagnosis of
DVT was confirmed by a positive report of venous ultra-
sound or venography, whereas the diagnosis of PE was
considered confirmed in the presence of either a positive
angiogram or a ventilation-perfusion scan with two or more
mismatched defects. Idiopathic DVT or PE was defined as
occurring in the absence of known malignancy or recent
trauma or surgery. Recurrent DVT or PE was defined as any
VTE event occurring greater than three months after the
index event. For each patient with confirmed DVT or PE,
DNA was extracted and assayed for the presence or absence
of the prothrombin mutation and factor V Leiden by
polymerase chain reaction-based assay systems described
elsewhere (1,4,8).
Because the 218 men who suffered a first VTE had
different lengths of follow-up after their initial event,
person-years of exposure were calculated for each partici-
pant. For individuals suffering a recurrent VTE, exposure
was defined as the time between diagnoses of the first and
second VTE. For those who did not suffer a recurrent event,
exposure was calculated as the time between diagnosis of the
first VTE and March 1999. For those who did not suffer a
recurrent event but who died before March 1999, exposure
was calculated as the time between diagnosis of the first
VTE and the date of death. No participants were lost to
follow-up.
Incidence rates of recurrent VTE for patients with and
without the prothrombin mutation were computed as the
number of recurrent events divided by the total exposure
time for each group. The relative risk (RR) of recurrent
VTE associated with mutation was computed as the ratio of
the incidence rate among genetically affected men divided
by the incidence rate among those unaffected. Adjusted
estimates of risk were computed by use of Poisson regression
models that controlled for age, smoking habit, and body
mass index (BMI). All probability values are two-sided.
RESULTS
Of the 218 study participants, the first episode of venous
thromboembolism was classified as idiopathic in 101 (46%).
Fourteen of the 218 participants (6.4%) were carriers of the
prothrombin mutation, 29 (13.3%) were carriers of factor V
Leiden, and 3 (1.4%) were carriers of both mutations. No
patients were homozygous for either the prothrombin mu-
tation or factor V Leiden. Overall, 29 participants (13.3%)
developed recurrent VTE over a mean follow-up period of
7.3 years.
As shown in Table 1, (35.7%) of the 14 study participants
heterozygous for the prothrombin mutation developed re-
current VTE (incidence rate 5 8.70 per 100 person-years),
whereas 24 (11.8%) of the 204 individuals who did not carry
the mutation developed a recurrent event (incidence rate 5
1.76 per 100 person-years). Thus, the RR for recurrent
VTE associated with the prothrombin mutation was 4.93
(95% confidence interval [CI] 1.9–12.9; p 5 0.001); in
multivariate analyses controlling for age, smoking and BMI,
the adjusted RR was 5.28 (95% CI 2.0–14.0; p 5 0.001).
Among individuals in whom the initial VTE was classi-
fied as idiopathic, 4 of the 7 carriers of the prothrombin
mutation developed a recurrent event (57.1%; incidence
rate 5 12.79 per 100 person-years), as compared to 17 of
the 94 without the prothrombin mutation (18.1%; incidence
rate 5 2.44 per 100 person-years) (Table 2). Thus, the RR
for recurrent VTE in this subgroup (5.24; 95% CI 1.8–15.6;
p 5 0.003) was similar to that observed in the cohort as a
whole.
The effects of isolated versus combined mutation on
rates of recurrent VTE are shown in Figure 1. As
displayed, of the 178 study participants who carried
Abbreviations and Acronyms
BMI 5 body mass index
DVT 5 deep vein thrombosis
PE 5 pulmonary embolism
PHS 5 Physicians’ Health Study
PREVENT 5 Prevention of Recurrent Venous
Thromboembolism Trial
VTE 5 venous thromboembolism
Table 1. Incidence Rates of Recurrent Venous Thromboembolism Among 218 Men According to Presence or Absence of the








Ratio (Crude) p Value
Incidence Rate
Ratio (Adjusted) p Value
Total cohort 218 29 (13.3) 1418.3 2.04 — — — —
PT present 14 5 (35.7) 57.5 8.70 4.93 0.001 5.28 0.001
PT absent 204 24 (11.8) 1360.8 1.76 Referent Referent Referent Referent
*Incidence rates calculated per 100 person-years of exposure. Incidence Rate Ratios derive from a comparison of the incidence rate among those with the prothrombin mutation
to those without mutation (referent group). Variables included in adjusted analyses are age at index event, body mass index and smoking habit (past, current, never).
PT 5 prothrombin mutation.
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neither the prothrombin mutation nor factor V Leiden,
19 (10.7%) suffered a recurrent event. By contrast,
recurrent VTE occurred among 2 (18.2%) of the 11
participants with isolated prothrombin mutation, 5 of 26
(19.2%) with isolated factor V Leiden mutation, and 3 of
3 participants heterozygous for both mutations (100%).
Similar effects were observed in the subgroup of those
who initially presented with idiopathic VTE.
Among the total cohort, the mean time between initial
and recurrent VTE was 37.6 months (range 3 to 98
months). Carriers of the prothrombin mutation devel-
oped recurrent VTE at a mean time of 30.4 months
(range 9 to 98 months) after their initial event, whereas
those without the prothrombin mutation developed re-
current VTE at an average of 33.2 months (range 3 to 87
months). The times between initial and recurrent VTE
for the three participants who carried both the prothrom-
bin mutation and factor V Leiden were 12, 21, and 98
months, respectively. Of the three participants who
suffered more than one recurrent event during follow-up,
one carried the prothrombin mutation.
DISCUSSION
In this prospective study of 218 men with a first episode of
VTE, carriers of the G20210A mutation in the prothrom-
bin gene were at significantly increased risk for recurrent
thromboembolic events. Specifically, over a mean follow-up
period of 7.3 years, the recurrence rate was 35.7% among
carriers of the prothrombin mutation as compared to 11.8%
among unaffected individuals (RR 5 4.97; p 5 0.001). In
these data, the highest recurrence rates were observed
among those with both the prothrombin mutation and
factor V Leiden (100%), intermediate rates were observed
among those with isolated mutations (18% to 20%), and the
lowest rates were observed among genetically unaffected
individuals (10%). Similar findings were present in the
subgroup of study participants in whom the index VTE was
classified as idiopathic. In the present study, virtually all
events occurred after cessation of oral anticoagulant therapy.
Co-inheritance of coagulation defects. Prior prospective
studies have not reported an increase in risk of recurrent
VTE among carriers of the prothrombin mutation (12,13).
However, these studies were limited to follow-up periods
between 24 and 48 months. By contrast, mean follow-up in
our study was 7.3 years. Thus, we believe our data provide
important long-term evidence regarding the role of inher-
ited hypercoagulability in the pathogenesis of VTE. In
addition, the current prospective data provide further evi-
dence that co-inheritance of multiple hypercoagulable de-
fects results in significantly increased risks of recurrent
venous thromboembolism, corroborating recent retrospec-
tive findings among carriers of both the prothrombin
mutation and factor V Leiden (14,16). As such, the current
data additionally extend prior work describing gene-gene
and gene-environment interactions (17) between several
defects of anticoagulation including hyperhomocysteinemia
Table 2. Incidence Rates of Recurrent Venous Thromboembolism Among the Subgroup of Men With an Initially Idiopathic Event,










Ratio (Crude) p Value
Incidence Rate
Ratio (Adjusted)* p Value
Total cohort 101 21 (20.8) 728.2 2.88 — — — —
PT present 7 4 (57.1) 31.3 12.79 5.24 0.003 5.74 0.002
PT absent 94 17 (18.1) 696.9 2.44 Referent Referent Referent Referent
PT 5 prothrombin mutation.
*Incidence rates calculated per 100 person-years of exposure. Incidence Rate Ratios derive from a comparison of the incidence rate among those with the prothrombin mutation
to those without mutation (referent group). Variables included in adjusted analyses are age at index event, body mass index and smoking habit (past, current, never).
Figure 1. Rates of recurrent venous thromboembolism (VTE) based on the presence or absence of the prothrombin and factor V Leiden mutations.
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(18) and relative deficiencies of protein C, protein S, and
anti-thrombin III (2).
Clinical implications. From a clinical perspective, the
increase in risk of recurrent thromboembolic events
associated with the prothrombin mutation has several im-
plications. On the one hand, randomized clinical trials
demonstrate that, among individuals with a first thrombo-
embolic event, anticoagulation with full-dose warfarin for a
period of six months reduces the rate of recurrent VTE
compared to regimens of three months or less (19). Simi-
larly, “indefinite” therapy with full-dose warfarin has shown
efficacy among those with idiopathic events (20) and among
those with a history of multiple prior episodes of thrombosis
(21). Thus, on the basis of these data, one might hypothe-
size that genetically susceptible individuals should be tar-
geted for more aggressive anticoagulation regimens.
On the other hand, conflicting reports for both the
prothrombin mutation (12,13) and factor V Leiden (9–12)
indicate that there is no current consensus that genetically
affected individuals are necessarily at levels of risk high
enough to warrant such an approach. This issue is of
particular importance because studies of full-dose warfarin
have consistently demonstrated increased risks of hemor-
rhage such that the net benefit-to-risk ratio for lifelong
anticoagulation remains uncertain, even among the highest-
risk subgroups.
Need for clinical trials. Given this situation, whether or
not genetically affected individuals require more prolonged
anticoagulation to prevent recurrent VTE is unknown.
Thus, in this context, we believe the current data strongly
support the need for aggressive enrollment of both geneti-
cally affected and unaffected patients into ongoing clinical
trials designed to evaluate directly the net benefit-to-risk
ratio associated with long-term anticoagulation (22). Opti-
mally, such trials should include consideration of low-dose
warfarin regimens, such as the target international normal-
ized ratio range of 1.5 to 2.0 currently being tested in the
Prevention of Recurrent Venous Thromboembolism Trial
(PREVENT), an ongoing federally funded project enrolling
VTE patients with and without genetic determinants of
hypercoagulability (23).
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